PIK3CA activating mutations are associated with more disseminated disease at presentation and earlier recurrence in glioblastoma

Table 1 Patient and tumor characteristics

	Total	PIK3CA mutant	PIK3CA wildtype	P value
Number of patients	157	13	144
(male patient)	(91 male)	(9 male)	(82 male)	0.56
Age	median 58 (23–85)	mean 49.4 ± 15.9	mean 58.1 ± 12.1	0.02^*
KPS score	median 90 (60–100)	mean 92.3 ± 7.3	mean 87.7 ± 10.4	0.048^*
Gross total resection	69 (44.0%)	5 (38.5%)	64 (44.4%)	0.78
IDH1 mutation	12/157 (7.6%)	0/13 (0.0%)	12/144 (8.3%)	0.60
MGMT promoter methylation	60/120 (50.0%)	8/11 (72.7%)	52/109 (47.7%)	0.20
EGFR amplification	63/143 (44.1%)	2/12 (16.7%)	61/131 (46.6%)	0.07

* Statistical significance: P ≤ 0.05
Abbreviations: KPS, Karnofsky performance status; IDH1, isocitrate dehydrogenase 1; MGMT O⁶-methylguanine-DNA methyltransferase

ISSN: 2051-5960